Davita Inc vs UDR Inc. Common Stock — how do they compare? Davita Inc trades at $180.7 (market cap $11.53B), while UDR Inc. Common Stock trades at $33.96 (market cap $10.91B). The key difference: Davita Inc and UDR Inc. Common Stock are close in size by market cap, and UDR Inc. Common Stock pays a 5.12% dividend while Davita Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Davita Inc for 114 Days and UDR Inc. Common Stock for 0 Days on average.
| DVA | UDR | |
|---|---|---|
Market Cap | $11.53B | $10.91B |
Volume | 444,368 | 3,347,873 |
Sector | Health | Real Estate |
52-Week High | $240.96 | $41.24 |
52-Week Low | $103.87 | $33.27 |
Typical Hold Time | 114 Days | 0 Days |
Enterprise Value | $24.25B | $16.95B |
Dividend Yield | — | 5.12% |
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $182.08, up 0.17% with a bullish technical outlook. The stock shows strong fundamentals with consistent earnings beats (Q4 2025-Q2 2026), revenue growth from $11.6B to $13.6B (2022-2025), and attractive valuation at P/E 15.43. Recent partnership expansion with Humana for value-based kidney care and institutional buying by BlackRock ($547.5M) support positive momentum. Operating cash flow remains robust at $1.89B (2025), though net cash flow turned negative due to debt repayments.
Outlook: DVA offers upside to consensus target ($235.67) with 29% potential, backed by earnings growth and strategic partnerships. Risks include high debt (debt-to-asset 65.55%), regulatory pressures, and margin volatility. Analyst consensus leans Hold (52.17%) amid balanced growth prospects and financial leverage concerns.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →UDR, Inc. is a self-administered real estate investment trust that owns, operates, develops, and redevelops multifamily apartment communities across targeted US markets. The company generates income primarily through leasing apartment homes, with a portfolio concentrated in coastal and Sunbelt metropolitan areas.
Read more on UDR →